Kim Drapkin, a qualified NASDAQ financial expert and experienced Chief Financial Officer, has served as the audit chair of multiple public companies. Having also served on board transaction, compensation and audit committees, she brings more than 30 years of experience working with private and publicly traded biotechnology and pharmaceutical companies, including:

• building and leading finance functions
• raising capital
• leading strategic financial planning
• significant IPO, fund raising, merger and operational experience

In addition to building companies, advising and providing financial expertise, Ms. Drapkin has extensive experience serving on and with boards of directors. In addition to Acumen, Ms. Drapkin currently serves on the boards of:

• Imugene (ASU: IMU) and is the chair of the audit committee and member of the remuneration committee, and
• Kineta (Nasdaq: KA) and is a member of the audit committee (reverse merged into YMTX)

Previously she has served on the board of directors at Proteostasis Therapeutics (Nasdaq: PTI) from 2019 – 2020 and remained on the board of Yumanity Therapeutics (Nasdaq: YMTX) after they reversed merged into PTI in December 2020 through their reverse merger in December 2022.  She served as the PTI chair of the audit committee and was a member of the governance and compensation committees. At Yumanity, Ms. Drapkin served as member of the audit and compensation committees. At both PTI and Yumanity, Ms. Drapkin served on the transaction committees. Ms. Drapkin has served as a Trustee to an independent school and has been a member of the Dana Farber Cancer Institute Patient and Family Advisory Council since 2018.